These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 19476473

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
    Melzer Cohen C, Davis C, Shalev V, Chodick G.
    J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
    [Abstract] [Full Text] [Related]

  • 23. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 24. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G, Wang W, Li L, Ma J, Lv X, Yang M, Wang W, Woloschak M, Lukashevich V, Kothny W.
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [Abstract] [Full Text] [Related]

  • 29. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
    Banerji MA, Purkayastha D, Francis BH.
    Diabetes Res Clin Pract; 2010 Nov; 90(2):182-90. PubMed ID: 20655609
    [Abstract] [Full Text] [Related]

  • 30. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Nov; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 31. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.
    Cochrane Database Syst Rev; 2017 Feb 27; 2(2):CD009966. PubMed ID: 28238223
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.
    Foley JE, Sreenan S.
    Horm Metab Res; 2009 Dec 27; 41(12):905-9. PubMed ID: 19705345
    [Abstract] [Full Text] [Related]

  • 33. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S.
    Diabetologia; 2007 Jun 27; 50(6):1148-55. PubMed ID: 17387446
    [Abstract] [Full Text] [Related]

  • 34. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
    Shestakova MV, Suhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il'in AV, Dedov II.
    Ter Arkh; 2013 Jun 27; 85(8):49-55. PubMed ID: 24137964
    [Abstract] [Full Text] [Related]

  • 35. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M, Veselá V, Gerle J, Brada M, Dohnalová L, Edelsberger T, Houdová J.
    Vnitr Lek; 2013 Dec 27; 59(12):1049-56. PubMed ID: 24350936
    [Abstract] [Full Text] [Related]

  • 36. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C, Jing W, Xiaochun H, Yuyu T, Shunyou D, Yingyu F.
    Curr Med Res Opin; 2016 Jun 27; 32(6):1131-6. PubMed ID: 26950829
    [Abstract] [Full Text] [Related]

  • 37. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
    Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M.
    Diabetes Obes Metab; 2009 Oct 27; 11(10):978-86. PubMed ID: 19614942
    [Abstract] [Full Text] [Related]

  • 38. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
    Schweizer A, Couturier A, Foley JE, Dejager S.
    Diabet Med; 2007 Sep 27; 24(9):955-61. PubMed ID: 17509069
    [Abstract] [Full Text] [Related]

  • 39. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.
    Haidinger M, Werzowa J, Voigt HC, Pleiner J, Stemer G, Hecking M, Döller D, Hörl WH, Weichhart T, Säemann MD.
    Trials; 2010 Oct 06; 11():91. PubMed ID: 20925938
    [Abstract] [Full Text] [Related]

  • 40. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.
    Diabetes Care; 2007 Feb 06; 30(2):217-23. PubMed ID: 17259484
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.